Related Experiment Video
Updated: Sep 23, 2025

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
Extracorporeal membrane oxygenation support in children with severe coronavirus disease-2019: A case series
Candice Torres de Melo Bezerra Cavalcante1,2, Andrea Consuelo de Oliveira Teles1, Isabel Cristina Leite Maia1
1Hospital Dr. Carlos Alberto Studart Gomes, Av. Washington Soares, 1321 - Edson Queiroz, Fortaleza, CE CEP 60811-905, Brazil.
Insights
Extracorporeal membrane oxygenation (ECMO) provided life support for six children with severe COVID-19 respiratory failure. This pediatric ECMO case series showed a 66.7% survival rate, highlighting its potential in critical pediatric cases.
Area of Science:
- Pediatric Critical Care Medicine
- Infectious Diseases
- Cardiopulmonary Support
Background:
- COVID-19 predominantly impacts adults, with lower prevalence but potential for severe disease in children.
- A subset of pediatric COVID-19 patients develop severe hypoxemic respiratory failure refractory to conventional treatments.
- Extracorporeal membrane oxygenation (ECMO) is a potential rescue therapy for severe pediatric respiratory failure.
Purpose of the Study:
- To report a series of six pediatric cases of COVID-19 requiring ECMO support.
- To evaluate the outcomes of children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection treated with ECMO.
- To assess the viability of ECMO as an intervention for refractory hypoxemic respiratory failure in children.
Main Methods:
- Observational, retrospective case series.
- Data collected from pediatric intensive care units between March 2020 and June 2021.
- Analysis of sociodemographic, clinical, and laboratory data for children on ECMO.
Main Results:
- Six children (median age 1.8 years) with severe COVID-19 respiratory failure received ECMO.
- Mean ECMO duration was 11 days, with a mean ventilation time of 20.5 days.
- Survival to hospital discharge was 66.7% (4/6), with one in-hospital mortality and one death post-decannulation.
Conclusions:
- ECMO can be a life-saving intervention for select pediatric patients with severe COVID-19 and refractory hypoxemic respiratory failure.
- Despite a 33.3% mortality rate in this series, ECMO offers a chance of survival when conventional therapies fail.
- Further research is warranted to optimize ECMO use in pediatric COVID-19 critical care.
Background:
The coronavirus disease-2019 (COVID-19) pandemic has predominantly affected the adult population, but with a significantly lower prevalence in children. Most pediatric patients with COVID-19 have mild course; however, a small number progressed to acute respiratory distress syndrome, hypoxemia, despite optimized conventional therapies. Thus, this study aimed to report a series of six cases of children with severe acute respiratory syndrome coronavirus 2 infection who were supported by extracorporeal membrane oxygenation (ECMO) due to refractory hypoxemic respiratory failure.
Methods:
This observational, retrospective, and descriptive study reported a series of cases. Data were retrospectively collected from the medical records of patients who were admitted to the Pediatric Cardiologic Intensive Care of Hospital Dr. Carlos Alberto Studart Gomes and Hospital Regional da Unimed, between March 1, 2020, and June 30, 2021. Sociodemographic, clinical, and laboratory data were analyzed.
Findings:
The median age was 1.8 years (range: 0.4-14.5 years), 66.7% were males, and weight varied from 13 to 110 kg. The mean time between the onset of symptoms and cannulation, ECMO duration, and ventilation time were 15 days (range: 6-24 days)], 11 days (range: 6-19 days), and 20.5 days (range: 14-33 days), respectively. Five (83.3%) children were successfully decannulated and four survived with hospital discharge. One child died on ECMO support due to multiple organ dysfunction syndromes after 13 days and another one died 3 days after decannulation due to extensive hemorrhagic stroke. Our case series revealed a 33.3% in-hospital mortality rate. ECMO appears as a viable intervention in selected patients who failed conventional therapies in the pediatric population.
Funding:
This observational study received no funding.
Related Concept Videos
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-IV
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

